ORGO Organogenesis Holdings Inc
Price (delayed)
$3.77
Market cap
$499.81M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.06
Enterprise value
$511.27M
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's
Highlights
ORGO's debt is down by 13% year-on-year and by 4.1% since the previous quarter
The quick ratio has grown by 11% since the previous quarter and by 10% year-on-year
The EPS has dropped by 160% year-on-year but it has surged by 54% since the previous quarter
The net income has plunged by 157% YoY but it has soared by 55% from the previous quarter
Key stats
What are the main financial stats of ORGO
Market
Valuations
Earnings
Shares outstanding
132.58M
Market cap
$499.81M
Enterprise value
$511.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.79
Price to sales (P/S)
1.1
EV/EBIT
N/A
EV/EBITDA
40.79
EV/Sales
1.12
Revenue
$455.04M
Gross profit
$342.58M
Net income
-$7.38M
EBIT
-$12.75M
EBITDA
$12.54M
Free cash flow
$3.89M
Per share
Balance sheet
Liquidity
EPS
-$0.06
EPS diluted
-$0.06
Free cash flow per share
$0.03
Book value per share
$2.1
Revenue per share
$3.43
TBVPS
$3.05
Total assets
$446.3M
Total liabilities
$167.75M
Debt
$106.38M
Equity
$278.55M
Working capital
$161.23M
Debt to equity
0.38
Current ratio
3.09
Quick ratio
2.54
Net debt/EBITDA
0.91
Margins
Efficiency
Dividend
EBITDA margin
2.8%
Gross margin
75.3%
Net margin
-1.6%
Operating margin
-2.8%
Return on assets
-1.6%
Return on equity
-2.7%
Return on invested capital
-3.7%
Return on capital employed
-3.5%
Return on sales
-2.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORGO stock price
How has the Organogenesis Holdings stock price performed over time
Intraday
-0.79%
1 week
6.8%
1 month
19.3%
1 year
8.02%
YTD
17.81%
QTD
17.81%
Financial performance
How have Organogenesis Holdings's revenue and profit performed over time
Revenue
$455.04M
Gross profit
$342.58M
Operating income
-$12.81M
Net income
-$7.38M
Gross margin
75.3%
Net margin
-1.6%
The net income has plunged by 157% YoY but it has soared by 55% from the previous quarter
Organogenesis Holdings's operating income has plunged by 157% YoY and by 16% from the previous quarter
Organogenesis Holdings's operating margin has shrunk by 156% YoY and by 12% QoQ
ORGO's net margin has dropped by 155% year-on-year but it has soared by 57% since the previous quarter
Growth
What is Organogenesis Holdings's growth rate over time
Valuation
What is Organogenesis Holdings stock price valuation
P/E
N/A
P/B
1.79
P/S
1.1
EV/EBIT
N/A
EV/EBITDA
40.79
EV/Sales
1.12
The EPS has dropped by 160% year-on-year but it has surged by 54% since the previous quarter
The P/B is 63% below the 5-year quarterly average of 4.9 but 19% above the last 4 quarters average of 1.5
ORGO's equity is up by 6% QoQ
ORGO's P/S is 42% below its 5-year quarterly average of 1.9 but 22% above its last 4 quarters average of 0.9
Efficiency
How efficient is Organogenesis Holdings business performance
The return on invested capital has dropped by 158% year-on-year and by 19% since the previous quarter
The return on sales has dropped by 156% year-on-year and by 17% since the previous quarter
Organogenesis Holdings's return on equity has shrunk by 156% YoY but it has surged by 55% QoQ
The ROA has plunged by 155% YoY but it has soared by 56% from the previous quarter
Dividends
What is ORGO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORGO.
Financial health
How did Organogenesis Holdings financials performed over time
ORGO's total assets is 166% greater than its total liabilities
The current ratio has grown by 13% from the previous quarter and by 12% YoY
The quick ratio has grown by 11% since the previous quarter and by 10% year-on-year
ORGO's debt is 62% smaller than its equity
The debt to equity is down by 14% year-on-year and by 10% since the previous quarter
ORGO's debt is down by 13% year-on-year and by 4.1% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.